Asthma: as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate‑to‑severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. Limitation of Use: DUPIXENT is not indicated for the relief of acute bronchospasm or status asthmaticus.

Atopic Dermatitis: for the treatment of adult and pediatric patients aged 6 months and older with moderate‑to‑severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.

Chronic Rhinosinusitis with Nasal Polyps: as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

Eosinophilic Esophagitis: for the treatment of adult and pediatric patients aged 12 years, weighing at least 40 kg, and older with eosinophilic esophagitis (EoE).

Eosinophilic Esophagitis: for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).

Prurigo Nodularis: for the treatment of adult patients with prurigo nodularis (PN).

^aThe mechanism of dupilumab action has not been definitively established.